Prostate Cancer Collection

Abiraterone prostate cancer drug molecule
Abiraterone prostate cancer drug, molecular model. Abiraterone blocks the production of testosterone by inhibiting an enzyme involved in its formation. This leads to the death of the cancerous cells

Prostate cancer, light micrograph F005 / 6093
Prostate cancer. Light micrograph of a section through a carcinoma (cancer) of the prostate. Magnification: x200 when printed at 10 centimetres wide

Enzalutamide prostate cancer drug F007 / 0146
Enzalutamide prostate cancer drug, molecular model. Atoms are represented as spheres and are colour-coded: hydrogen (white), carbon (grey), oxygen (red), sulphur (yellow)

Enzalutamide prostate cancer drug F007 / 0145
Enzalutamide prostate cancer drug, molecular model. Atoms are represented as spheres and are colour-coded: hydrogen (white), carbon (grey), oxygen (red), sulphur (yellow)

Bicalutamide drug binding to receptor. Molecular model of the drug bicalutamide (lower right) binding to a receptor protein (ribbons)

Bicalutamide drug, molecular model. Bicalutamide is a drug used in the treatment of prostate cancer and hirsutism. It is an oral non-steroidal anti-androgen that works by binding to androgen

Enzalutamide drug, molecular model. Enzalutamide is a drug used in the treatment of castration-resistant prostate cancer. It is an experimental androgen receptor antagonist that works by binding to

PLGA microspheres, SEM
PLGA microspheres, coloured scanning electron micrograph (SEM). PLGA, or poly(lactic-co-glycolic acid), is a copolymer used in a variety of biomedical devices such as grafts, sutures (stitches)

Breast cancer protein and cancer cell C016 / 4613
Artwork showing a molecular model of breast cancer type 1 susceptibility (BRCA1) protein (left) and a cancer cell (right)

Breast cancer protein and cancer cell C016 / 4612
Artwork showing a molecular model of breast cancer type 1 susceptibility (BRCA1) protein (left) and a cancer cell (right)

Breast cancer protein and cancer cell C016 / 4610
Artwork showing a molecular model of breast cancer type 1 susceptibility (BRCA1) protein (left) and a cancer cell (right)

Breast cancer protein and cancer cell C016 / 4608
Artwork showing a molecular model of breast cancer type 1 susceptibility (BRCA1) protein (left) and a cancer cell (right)

Breast cancer and cancer protein molecule C016 / 4604
Breast cancer. Wireframe computer artwork of a woman with breast cancer. There is a malignant (cancerous) tumour (pink) in the patients right breast

Breast cancer protein and cancer cell C016 / 4600
Artwork showing a molecular model of breast cancer type 1 susceptibility (BRCA1) protein (left) and a cancer cell (right)

Breast cancer protein and cancer cell C016 / 4598
Artwork showing a molecular model of breast cancer type 1 susceptibility (BRCA1) protein (left) and a cancer cell (right)

Breast cancer protein molecule C016 / 4455
Breast cancer protein. Molecular model of breast cancer type 1 susceptibility (BRCA1) protein. This protein is found in breast and other tissue

Breast cancer protein molecule C016 / 4454
Breast cancer protein. Molecular model of breast cancer type 1 susceptibility (BRCA1) protein. This protein is found in breast and other tissue

Breast cancer protein molecule C016 / 4453
Breast cancer protein. Molecular model of breast cancer type 1 susceptibility (BRCA1) protein. This protein is found in breast and other tissue

Breast cancer protein molecule C016 / 4450
Breast cancer protein. Molecular model of breast cancer type 1 susceptibility (BRCA1) protein. This protein is found in breast and other tissue

Human tumour protein p63 C016 / 2681
Human tumour protein p63. Molecular model of the tetramerization domain of the human tumour protein p63, encoded by the TP63 gene

Human tumour protein p63 C016 / 2680
Human tumour protein p63. Molecular model of the tetramerization domain of the human tumour protein p63, encoded by the TP63 gene

Prostate cancer cell, SEM C013 / 5012
Prostate cancer cell, coloured scanning electron micrograph (SEM). The uneven surface of this cell is typical of cancer cells

Prostate cancer cell, SEM C013 / 5011
Prostate cancer cell, coloured scanning electron micrograph (SEM). The uneven surface of this cell is typical of cancer cells

All Professionally Made to Order for Quick Shipping

"Prostate Cancer: Battling on the Field and in the Lab" In a clash between Arsenall and Brighton and Hove Albion, football took center stage. But beyond the pitch, another battle rages on - prostate cancer. This disease affects millions of men worldwide, demanding attention both on and off the field. Scientists tirelessly work to find effective treatments for this aggressive form of cancer. One promising molecule is Abiraterone, a prostate cancer drug that shows great potential in combating the disease. Its structure holds hope for patients seeking new treatment options. Another weapon in our arsenal against prostate cancer is Enzalutamide, a powerful drug designed to target specific receptors associated with this type of cancer. Researchers are exploring its potential to halt tumor growth and improve patient outcomes. Microscopic images reveal the intricate nature cells under scrutiny. These light micrographs provide valuable insights into their behavior, aiding scientists in developing targeted therapies. Artwork depicting prostate cancer serves as a reminder of the urgency surrounding this disease. Through creative expression, artists raise awareness about its impact on individuals and society as a whole. Bicalutamide emerges as yet another crucial player in fighting against prostate cancer by binding to receptors involved in its progression. Understanding how drugs like Bicalutamide interact with these receptors brings us closer to personalized treatment strategies tailored for each patient's unique needs. As we witness battles unfold both on football fields and within laboratories, it becomes evident that defeating prostate cancer requires teamwork from all fronts – researchers, healthcare professionals, patients, families, and communities alike. Together we can tackle this formidable opponent head-on until victory is achieved – a world free from the grip of prostate cancer.